Skip to main content

Table 3 Amplification hotspots associated with clinical outcome

From: High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer

Cytoband

Genes

nAMP

OS HR (95% CI) p value

TTDM HR (95% CI) p value

8q22.3

EDD1, AZIN1

17

2.2 (1.1-4.6) 0.02

2.1 (0.9-5) 0.09

8q22.3

WDSOF1

15

2.2 (1.1-4.7) 0.03

1.9 (0.7-4.9) 0.17

8q24.11

THRAP6

23

1.9 (1-3.8) 0.04

2.1 (0.9-4.5) 0.06

8q24.12

DCC1, DEPDC6

23

1.9 (1-3.7) 0.05

2.1 (0.9-4.5) 0.06

8q24.13

SQLE, SPG8

23

2 (1-3.9) 0.03

2.2 (1-4.7) 0.05

11q14.1

NDUFC2, ALG8, USP35

10

2.5 (1.1-6) 0.03

2.4 (0.8-6.8) 0.09

5-amp

5-amp

37

2.6 (1.5-4.6) 3 × 10-4

3.0 (1.6-5.8) 5 × 10-4

  1. Amplification hotspots significantly associated with either overall survival (OS) or time to distant metastasis (TTDM). The cytoband locations, genes located in amplified hotspots that showed coordinate overexpression, the number of samples with amplification (nAMP), hazard ratio (HR), 95% confidence interval and log-rank test p values are given.